Substituted Imidazole ALK5 Inhibitors With Improved Tissue Distribution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ALK5 inhibitors for the TGF-β signaling pathway have limitations in therapeutic indices, formulation, and tissue distribution, necessitating the development of additional compounds with improved efficacy for treating diverse diseases, particularly in oncology.
Innovation Solution
Development of low molecular weight substituted imidazoles that inhibit the TGF-β signaling pathway, targeting Type I and Type II receptors, for the treatment of various diseases including oncology indications such as lung cancer, gastric cancer, and glioblastoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ALK5 inhibitors are used to block TGF-β signaling, then the signaling pathway is inhibited, but therapeutic indices are limited and tissue distribution is suboptimal
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of ALK5 inhibitors through various substitutions including heteroaryl groups, cycloalkyl groups, and different linkage types. These structural parameter changes result in compounds with improved therapeutic indices and optimized tissue distribution properties while maintaining TGF-β signaling inhibition activity
Solution Approach 2:
The patent employs composite material principles by creating molecules that combine multiple functional groups and structural elements (heteroaryl rings, cycloalkyl groups, amide linkages, and aromatic substituents) into a single inhibitor compound. This composite structure allows simultaneous optimization of binding affinity, selectivity, and tissue distribution characteristics
2Reliability
If existing ALK5 inhibitors are used, then TGF-β signaling is blocked, but formulation properties are unfavorable
Solution Approach 1:
The patent modifies formulation properties by changing physical and chemical parameters of the inhibitor compounds including molecular weight, lipophilicity, and solubility characteristics through systematic structural variations. These parameter changes enable improved formulation options and administration routes while preserving biological efficacy
3Reliability
If existing ALK5 inhibitors are used, then kinase domain is blocked, but additional compound classes are needed to probe potential efficacy in diverse diseases
Solution Approach 1:
The patent applies universality by designing a series of ALK5 inhibitor compounds with a common pharmacophore that can be applied across multiple disease indications including oncology, fibrotic diseases, and inflammatory conditions. The core inhibitor structure provides universal TGF-β signaling blockade while substituent variations allow optimization for specific disease targets and tissue distributions
Data Source
AI summary
This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.